Treatment of hepatitis C cryoglobulinemia: Mission and challenges

Current Treatment Options in Gastroenterology

Volumn 9, Issue 6, 2006, Pages 497-507

  Kayali, Zeid ^b   LaBrecque, Douglas R ^a   Schmidt, Warren N ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PEGINTERFERON; PREDNISONE; RIBAVIRIN; RITUXIMAB; VIRUS ANTIBODY; VIRUS RNA;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; CYTOPENIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; VIRUS REPLICATION;

EID: 33751333505     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0006-7     Document Type: Review

References (69)

1. Miescher PA, Huang YP, Izui S: Type-II cryoglobulinemia. Semin Hematol 1995, 32:80-85.
2. Weintrobe MM, Buell MV: Hyperproteinemia associated with multiple myeloma. Bull Johns Hopkins Hosp 1933, 52:156.
3. Lerner AB, Watson CJ. Studies of cryoglobulins. Unusual purpura associated with the presence of high concentrations of cold precipitable serum globulin. Am J Med Sci 1947, 214:410-415.
4. Meltzer M, Franldin EC, Elias K et al.: Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966, 40:837-856.
5. Durand JM, Lefevre P, Harle JR, et al.: Cutaneous vasculitis and cryoglobulinaemia type II associated with hepatitis C virus infection. Lancet 1991, 337:499-500.
6. Choo QL, Kuo G, Weiner AJ, et al.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
7. Cacoub P, Fabiani FL, Musset L, et al.: Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994, 96:124-132.
8. Monti G, Galli M, Invernizzi F, et al.: Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995, 88:115-126.
9. Kayali Z, Buckwold VE, Zimmerman B, etal.: Hepatitis C, cryoglobulinemia, and cirrhosis: A meta-analysis. Hepatology 2002, 36:978-985.
10. Lunel F, Musset L, Cacoub P, et al.: Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994, 106:1291-1300.
11. Sene D, Limal N, Cacoub P: Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004, 19:357-381.
12. Brouet JC, Clauvel JP, Danon F, et al.: Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974, 57:775-788.
13. Agnello V, Chung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992, 327:1490-1495.
14. Schmidt WN, Stapleton JT, LaBrecque DR, et al.: Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology. Hepatology 2000, 31:737-744.
15. Willson RA: Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997, 92:4-17.
16. Vassilopoulos D, Calabrese LH: Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002, 46:585-597.
17. Schott P, Hartmann H, Ramadori G: Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanisms of cryoprecipitation and options of treatment. Histol Histopathol 2001, 16:1275-1285.
18. D'Amico G.: Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998, 54:650-671.
19. Tarantino A, Devecchi A, Montagnino G, et al.: Renal disease in essential mixed cryoglobulinemia. Long-term follow-up of 44 patients. Q J Med 1981, 50:1-30.
20. Kayali Z, Tan S, Shinkunas L, et al.: Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. J Viral Hepat 2006, In press.
21. Saadoun D, Asselah T, Resche-Rigon M, et al.: Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 2006, 43:1337-1345.
22. Gane EJ, Maertens G, Ducatteeuw A, et al.: Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Transplantation 1999, 67:78-84.
23. Rayhill SC, Kirby A, Voigt MD, et al.: Positive serum cryoglobulin is associated with worse outcome after liver transplantation for chronic hepatitis C. Transplantation 2005, 80:448-456.
24. Crovatto M, Ceselli S, Mazzaro C, et al.: HCV genotypes and cryoglobulinemia. Clin Exp Rheumatol 1995, 13(Suppl 13):S79-S82.
25. Frangeul L, Musset L, Cresta P, et al.: Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996, 25:427-432.
26. Zignego AL, Ferri C, Giannini C, et al.: Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996, 124:31-34.
27. Lindsay KL: Therapy of hepatitis C: overview. Hepatology 1997, 26(Suppl 1):S71-S77.
28. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
29. Glue P, Rouzier-Panis R, Raffanel C, et al.: A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000, 32:647-653.
30. Manns MP, McHutchinson JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
31. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485-1492.
32. Veldt BJ, Saracco G, Boyer N, et al.: Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004, 53:1504-1508.
33. National Institutes of Health (NIH) Panel: National Institutes of Health Consensus Statement of Management of Hepatitis C: 2002. Bethesda, MD: NIH; 2006:1-46.
34. Liang TJ, Rehermann B, Seeff LB, et al.: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000, 132:296-305.
35. Bacon BR, McHutchison JG: Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005, 11 (Suppl 10): S296-S306.
36. He Y, Katze MG: To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunol 2002, 15:95-119.
37. Bonomo L, Casato M, Afeltra A, et al.: Treatment of idiopathic mixed cryoglobulinemia with. alpha-interferon. Am J Med 1987, 83:726-730.
38. Casato M, Lagana B, Antonelli G, et al.: Long-term results of therapy with interferon-alpha for type-II essential mixed cryoglobulinemia. Blood 1991, 78:3142-3147.
39. Ferri C, Marzo E, Longombardo G, et al.: Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993, 81:1132-1136.
40. Mazzaro C, Lacchin T, Moretti M, et al.: Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13(Suppl 13):S181-S185.
41. Migliaresi S, Tirri G: Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995, 13(Suppl 13):S175-S18O.
42. Misiani R, Bellavita P, Fenili D, et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994, 330:751-756.
43. Adinolfi LE, Utili R, Zampino R, et al.: Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 1997, 9:1067-1072.
44. Calleja JL, Albillos A, Moreno-Otero R, et al.: Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999, 13:1179-1186.
45. Casaril M, Capra F, Gabrielli GB, et al.: Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy. J Interferon Cytokine Res 1996, 16:585-588.
46. Casato M, Agnello V, Pucillo LP, et al.: Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997, 90:3865-3873.
47. Cresta P, Musset L, Cacoub P, et al.: Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999, 45:122-128.
48. Hartmann H, Schott P, Polzien F, et al.: Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates [in German]. Z Gastroenterol 1995, 33:643-650.
49. Polzien F, Schott P, Mihm S, et al.: Interferon-alpha treatment of hepatitis C virus-associated mixed cryo-globulinemia. J Hepatol 1997, 27:63-71.
50. Tanaka K, Aiyama T, Imai J, et al.: Serum cryoglobulin and chronic hepatitis C virus disease among Japanese patients. Am J Gastroenterol 1995, 90:1847-1852.
51. Naarendorp M, Kallemuchikkal U, Nuovo GJ, et al.: Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001, 28:2466-2473.
52. Dammacco F, Sansonno D, Han JH, et al.: Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994, 84:3336-3343.
53. Lauta VM, DeSangro MA: Long-term results regarding the use of recombinant interferon alpha-2b in the treatment of II type mixed essential cryoglobulinemia. Med Oncol 1995, 12:223-230.
54. Cacoub P, Lidove O, Maisonobe T, et al.: Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002, 46:3317-3326.
55. Mazzaro C, Zorat F, Comar C, et al.: Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003, 30:1775-1781.
56. Zuckerman E, Keren D, Slobodin G, et al.: Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000, 27:2172-2178.
57. Schmidt WN, LaBrecque DR, Voigt MD, et al.: Combination antiviral therapy in patients with chronic hepatitis C and cryoglobulinemia. Hepatology 2001, 34:421A.
58. Luxon BA, Grace M, Brassard D, Bordens R: Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002, 24:1363-1383.
59. Mazzaro C, Zorat F, Caizzi M, et al.: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005, 42:632-638.
60. Cacoub P, Saadoun D, Limal N, et al.: PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005, 52:911-915.
61. Casato M, Lagana B, Antonelli G, et al.: Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 1991, 78:3142-3147.
62. Campise M, Tarantino A: Glomerulonephritis in mixed cyyoglobulinaemia: what treatment? Nephrol Dial Transplant 1999, 14:281-283.
63. Ferri C, Zignego AL, Pileri SA: Cryoglobulins. J Clin Pathol 2002, 55:4-13.
64. Garini G, Allegri L, Carnevali L, et al.: Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001, 38:E35.
65. Lamprecht P, Gause A, Gross WL: Cryoglobulinemic vasculitis. Arthritis Rheum 1999, 42:2507-2516.
66. D'Amico E, Chincoli C, Cacciatore F, et al.: Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study. Dig Dis Sci 2005, 50:2344-2347.
67. Quartuccio L, Soardo G, Romano G, et al.: Treatment of glomerulonephritis in type II mixed cryoglobulinemia with rituximab. Arthritis Rheum 2004, 50:S235.
68. Zaja F, De Vita S, Mazzaro C, et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834.
69. Murai H, Inaba S, Kira J, et al.: Hepatitis C virus associated cryoglobulinemic neuropathy successfully treated with plasma exchange. Artif Organs 1995, 19:334-338.